• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Bulletin: Thermo Fisher Scientific Inc. Ratings Unaffected By Plan To Acquire Phadia May 11 Product Image

Bulletin: Thermo Fisher Scientific Inc. Ratings Unaffected By Plan To Acquire Phadia May 11

  • Published: May 2011
  • Standard & Poors

Abstract
TORONTO (Standard & Poor's) May 19, 2011--Standard & Poor's Ratings Services said today that its ratings on Waltham, Mass.-based life science company Thermo Fisher Scientific Inc. (A/Stable/-) are unaffected by the company's plan to acquire Swedish specialty diagnostics company Phadia for roughly $3.5 billion in cash. Phadia develops and manufactures blood-based diagnostics systems for diagnosing and monitoring allergy and autoimmune diseases, a relatively high-margin, fast growing business. The acquisition will likely drive Thermo Fisher's leverage to over 3x and reduce funds from operations to debt to a level inconsistent with its modest financial risk profile. However, we believe that, given Thermo Fisher's long-standing commitment to a conservative financial risk profile and its stable, highly visible annual free cash flow generation...

Companies mentioned in this report are:
- Thermo Fisher Scientific Inc.

Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress READ MORE >

- Thermo Fisher Scientific Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS